Request Trial
wichy-shutterstock-com-1
Wichy / Shutterstock.com
29 October 2015EuropePhilip Webber

Are the Broad Institute’s CRISPR patents too broad?

The ability of the CRISPR/Cas9 system to make precisely targeted mutations in genes, including human genes, has taken the biotech industry by storm. It has been described by some as being the most important development in biology since the discovery of the structure of DNA by Watson and Crick in 1953.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026   A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.
Europe
Italian medtech startup beats larger US rival in UPC dispute
15 January 2026   Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.
Europe
Bayer secures key Denmark ruling as Xarelto faces expiry pressure
13 January 2026   As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.


Editor's picks

Final call: Who are the world’s best in-house counsel?
Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

Editor's picks

Europe
Final call: Who are the world’s best in-house counsel?
16 January 2026

More features

Novartis win blocks generics relitigating $7.8bn heart drug patent
Rooted rights: Lessons from plant patent infringement and invalidity cases
Skinny labels, big stakes: SCOTUS lines up the case of the year
Final call: Who are the world’s best in-house counsel?
Speciality pharma firm stumbles on bid to enforce Belbuca ruling
Italian medtech startup beats larger US rival in UPC dispute
Senior USPTO solicitor steps into private practice
Goodwin targets transatlantic patent work with London hire